Evidence map›Paper›PMID 33852204›Full record

Trial reportDiabetes, obesity & metabolism2021

Insulin secretion is a strong predictor for need of insulin therapy in patients with new-onset diabetes and HbA1c of more than 10%: A post hoc analysis of the EDICT study.

Siham Abdelgani, Curtiss Puckett, John Adams, Curtis Triplitt, Ralph A DeFronzo, Muhammad Abdul-Ghani

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes, obesity & metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Siham AbdelganiDivision of Diabetes, University of Texas Health Science Center and Texas Diabetes Institute, San Antonio, Texas, USA.
Curtiss PuckettDivision of Diabetes, University of Texas Health Science Center and Texas Diabetes Institute, San Antonio, Texas, USA.
John AdamsDivision of Diabetes, University of Texas Health Science Center and Texas Diabetes Institute, San Antonio, Texas, USA.
Curtis TriplittDivision of Diabetes, University of Texas Health Science Center and Texas Diabetes Institute, San Antonio, Texas, USA.
Ralph A DeFronzoDivision of Diabetes, University of Texas Health Science Center and Texas Diabetes Institute, San Antonio, Texas, USA.ORCID 0000-0003-3839-1724
Muhammad Abdul-GhaniDivision of Diabetes, University of Texas Health Science Center and Texas Diabetes Institute, San Antonio, Texas, USA.ORCID 0000-0003-4556-1787
The University of Texas Health Science Center at San Antonio · US

Funding

Ketones, Muscle Metabolism, and SGLT2 InhibitorsR01DK107680 · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · 2025 to 2025
$583k
NIDDK NIH HHS R01 DK107680
6 · The paper itself

Abstract

aimTo identify predictors of response to glucose-lowering therapy in patients with new-onset diabetes and very high HbA1c (>10%).

methodsThe study included EDICT participants with an initial HbA1c of more than 10% (N = 104). All subjects received a 75-g oral glucose tolerance test (OGTT) before initiation of therapy, and then were randomized to receive: (a) initial triple therapy with metformin, pioglitazone and exenatide versus (b) stepwise conventional therapy with metformin followed by glipizide and then glargine insulin to reduce HbA1c to less than 6.5%. Insulin secretion and insulin resistance were calculated with OGTT-derived indices.

resultsSixty-one per cent of participants in the conventional therapy group achieved HbA1c of less than 6.5% at 6 months without need of insulin therapy compared with 78% in the triple therapy group (P = NS). Insulin secretion at baseline was the strongest predictor of subjects who did not require insulin therapy; a cut point of CPEP

conclusionInsulin secretion in response to a 75-g OGTT predicts the need for insulin therapy at the time of type 2 diabetes (T2D) diagnosis. A cut point of 1.7 of CPEP

Indexed as

Diabetes Mellitus, Type 2InsulinBlood GlucoseGlycated HemoglobinHumansHypoglycemic AgentsInsulin SecretionBlood GlucoseGlycated HemoglobinHypoglycemic AgentsInsulinglucose controlinsulin secretiontype 2 diabetes

Identifiers

PMID33852204
PMCPMC8238899
OpenAlexW3156512759

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.